الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
The current results showed non-significant frequency of the heterozygous TP53 Pro47Ser genotype compared to the controls [4.2% vs. 2.9%, OR (GA vs. GG) = 1.49, 95% CI = 0.39-5.71, p=0.74]. On the other hand, the homozygous TP53 Pro47Ser genotype was showed non-significant frequency observed in the patients with CRC as compared to healthy controls [3.3% vs. 2.1%, OR (AA vs. GG) = 1.06, 95% CI = 0.35-5.63, p=0.70]. Cases also showed non- significant frequency of the combined heterozygous and homozygous genotypes TP53 Pro47Ser GA and AA genotypes compared to controls (7.5% vs. 5 %, OR = 1.54, 95% CI = 0.56-4.27, p=0.45). Interestingly, cases showed no significant frequencies of TP53 Pro47Ser A allele compared to controls [5.4% vs. 3.6%, OR = 1.55, 95% CI = 0.67-3.59, p = 0.39].
There was a significantly higher association of the combined genotypes of the homozygous wild types (rs1042522) /(rs1800371) (GG/GG) compared to controls [25.8% vs. 37.9%, OR= 0.57, 95% CI= 0.34-0.97, P= 0.04]. It was also noted that, there was no significant association of the combined genotypes (GG/GA) compared to controls [1.7% vs. 1.4%, OR= 1.17, 95% CI= 0.16-8.43, P= 1.0]. Regarding to the clinical parameters and risk factors (age, gender, family history, smoking, Dukes’ stage, tumor location, the histological grading and the tumor markers of colorectal cancer, the present study showed that none of them showed any correlation with combined heterozygous and homozygous Tp53 Arg72Pro and Pro47Ser genotypes (p > 0.05).